36293-01-3Relevant articles and documents
Synthesis, characterization, and DFT studies of a new chiral ionic liquid from (S)-1-phenylethylamine
Cui, Shuya,Wang, Tao,Hu, Xiaoli
, p. 778 - 784 (2014)
A new chiral ionic liquid was synthesized from (S)-1-phenylethylamine and it was studied by IR, Raman, polarimetry, NMR and X-ray crystal diffraction. Its vibrational spectral bands are precisely ascribed to the studied structure with the aid of DFT theor
Effect of chirality and redox potentials on the cytotoxicity of new ferrocene functionalized chiral tertiary amines
Roy, Hetal,Savani, Chirag J.,Singh, Vinay K.,Vennapu, Dushyanth R.
, (2021/08/03)
Optically pure enantiomeric pair viz. ferrocene functionalized chiral tertiary amines S,S-(-)-1 and R,R-(+)-2 have been synthesized from ferrocenylmethylamine to probe the influence of chirality and the redox potential on their anti-proliferative activity. Compounds were characterized by microanalysis, HPLC, 1H, 13C NMR, UV-visible, fluorescence, FTIR, thermogravimetric and crystallographic techniques. The single crystal X-ray diffraction (SCXRD) study revealed that the molecules of 1 holding S,S-chirality at benzylic carbons forms a fascinating M-helix while 2 holding R,R-chirality at benzylic carbons forms P-helix by involving intra- and intermolecular H-bonding interactions as verified by Hirshfeld surface analysis. Chirality-related influence was observed on the antiproliferative activity of enantiomeric pair and at the supramolecular level. For instance, enantiomer R,R-(+)-2 is found to be highly active against all the investigated human carcinoma cell lines MCF 7, IMR 32, HepG2, and immortal L132 cell lines. In particular, R,R-(+)-2 exhibited more than 10 folds better antiproliferation (IC 50: 6.35±0.19 μM) than other enantiomer S,S-(-)-1 (IC50: 65.96 ± 0.12 μM) and four folds better activity than highly successful anticancer drug, cisplatin (IC50: 24.3 ± 1.7 μM) against Hep G2 cell line. The electrochemical, DFT calculations and molecular docking study have been performed to justify the experimental outcomes.
(S)-N-(1-phenethyl) thioacetamide compound as well as medicinal composition and application thereof
-
Paragraph 0042; 0043; 0044; 0045, (2017/08/31)
The invention belongs to the field of medicinal chemicals, relates to a STAT3 inhibitor, and in particular to a (S)-N-(1-phenethyl) thioacetamide compound of a structure of formula (I) as shown in the specification, a medicinal composition of the compound as an STAT3 (Signal Transducer and Activator of Transcription 3) signal path inhibitor, and application of the compound in preparing anti-tumor medicines. Results of cell experiment show that the compound targets a Phe-Lys-Thr-Lys-Leu pentapeptide binding region in an STAT3 SH2 structure domain, then inhibits STAT3 protein monomer dimerization and silencing STAT3 signal transduction and functions, has a remarkable anti-tumor effect and good physical and chemical properties, is particularly capable of effectively preventing cell proliferative activity in breast cancer cells with high expression of STAT3 and HEL cells on which JAK2/STAT3 signal paths depend with JAK2 V671F mutation, and moreover is capable of effectively inhibiting phosphorylation of STAT3 in the breast cancer cells with high expression of STAT3 and expression of downstream target genes such as CyclinD1 and Bc1-2.